具体实施方式
以下结合具体实施例对本发明作进一步详细说明,但不用来限制本发明的范围。
所述原材料如无特别说明,均能从公开商业途径获得。
实施例1
(6S,8S,9S,10R,11S,13S,14S,17R)-11,17-二羟基-17-((E)-2-羟基-1-(羟基亚氨基)乙基)-6,10,13-三甲基-6,7,8,9,10,11,12,13,14,15,16,17-十二氢-3H-环戊烷[a]菲-3-酮肟
在室温下,向溶有甲强龙a(500mg,1.0eq)的甲醇溶液中加入乙酸钠(370mg,2.5eq)分批加入盐酸羟胺(203mg,2.2eq),室温反应6h,,TLC监测反应完毕后真空旋干溶剂。使用Biotage Isolera自动柱色谱仪,在EA和PE梯度中纯化,并接着在减压下干燥。得到米白色固体Z/E-1(510mg,95%)。而后进一步用RPHPLC,在MeOH和H2O梯度中纯化,并减压干燥得到纯化合物3(Z)-1(200mg)和化合物3(E)-1(248mg)。
化合物3(Z)-1:1H-NMR(600MHz,d6-DMSO)δH 0.629(m,1H),0.870-0.835(m,4H),1.051-1.035(d,3H),1.254-1.119(m,1H),1.323(s,3H),1.436-1.354(m,1H),1.604-1.590(m,2H),1.758-1.714(m,2H),1.995-1.969(m,2H),2.636-2.536(m,1H),2.734(m,1H),4.164-4.132(m,1H),4.274-4.225(m,2H),4.406-4.397(m,1H),4.589-4.560(m,1H),4.807(s,1H),6.116-6.087(m,1H),6.354-6.329(d,1H),6.446(s,1H),10.576(s,1H),10.796(s,1H);13C(600MHz,d6-DMSO)δC 18.24,18.62,23.45,23.60,31.71,32.73,32.83,39.96,43.51,43.67,47.07,50.90,55.74,56.94,67.76,85.67,104.83,121.59,141.73,148.76,159.72,161.47;LRMS(ES+)[C22H32N2O5+H]的计算值405.3实验值405.2。
化合物3(E)-1:1H-NMR(600MHz,d6-DMSO)δH 0.632-0.612(m,1H),0.875-0.832(m,4H),1.032-1.021(d,3H),1.254-1.119(m,1H),1.324(s,3H),1.368-1.354(m,1H),1.607-1.595(m,2H),1.760-1.709(m,2H),2.004-1.943(m,2H),2.511(m,1H),2.731(m,1H),4.157-4.127(m,1H),4.266-4.233(m,2H),4.408-4.402(m,1H),4.592-4.572(m,1H),4.809(s,1H),5.708(s,1H),6.519-6.501(d,1H),6.779-6.759(m,1H),10.522(s,1H),10.793(s,1H);13C(600MHz,d6-DMSO)δC 18.23,18.57,23.31,23.48,31.74,32.64,32.83,39.95,43.42,43.62,47.03,50.92,55.76,56.69,67.70,85.71,112.20,113.75,145.96,149.06,156.86,159.72;LRMS(ES+)[C22H32N2O5+H]的计算值405.3实验值405.2。
实施例2
(2E)-2-((6S,8S,9S,10R,11S,13S,14S,17R)-11,17-二羟基-3-(羟基亚氨基)-6,10,13-三甲基-6,7,8,9,10,11,12,13,14,15,16,17-十二氢-3H-环戊烷[a]菲-17-基)-2-(羟基亚氨基)乙酸乙酯
按照上文一般的合成方法中合成路线I、II中所示的方法,用合适的起始原料制备化合物2,并分离得到(3Z)-2和(3E)-2。
化合物3(Z)-2:1H-NMR(600MHz,d6-DMSO)δH 0.630(m,1H),0.863-0.835(m,4H),1.044-1.032(d,3H),1.255-1.122(m,1H),1.325(s,3H),1.366-1.352(m,1H),1.603-1.590(m,2H),1.758-1.712(m,2H),1.998-1.953(m,2H),2.632(m,1H),2.688(s,3H),2.733(m,1H),4.166-4.142(m,1H),4.259-4.227(m,2H),4.405-4.386(m,1H),4.806(s,1H),6.113-6.078(m,1H),6.345-6.327(d,1H),6.452(s,1H),10.574(s,1H),10.793(s,1H);13C(600MHz,d6-DMSO)δC 18.22,18.56,22.93,23.39,23.60,31.72,32.69,32.81,39.94,43.52,43.66,47.07,50.92,55.75,56.92,67.74,85.65,104.81,121.60,141.71,148.78,159.73,161.47,168.91;LRMS(ES+)[C24H34N2O6+H]的计算值447.3实验值447.2。
化合物3(E)-2:1H-NMR(600MHz,d6-DMSO)δH 0.628(m,1H),0.865-0.840(m,4H),1.038-1.025(d,3H),1.252-1.120(m,1H),1.327(s,3H),1.368-1.353(m,1H),1.605-1.596(m,2H),1.761-1.718(m,2H),2.002-1.956(m,2H),2.598(m,1H),2.730(m,4H),4.157-4.127(m,1H),4.263-4.237(m,2H),4.404-4.400(m,1H),4.807(s,1H),5.705(s,1H),6.518-6.502(d,1H),6.781-6.758(m,1H),10.524(s,1H),10.781(s,1H);13C(600MHz,d6-DMSO)δC 18.25,18.55,22.88,23.35,23.49,31.72,32.63,32.82,39.95,43.54,43.61,47.04,50.92,55.75,56.70,67.72,85.70,112.22,113.74,145.93,149.07,156.86,159.73,168.95;LRMS(ES+)[C24H34N2O6+H]的计算值447.3实验值447.2。
实施例3
(8S,9S,10R,11S,13S,14S,17R)-11,17-二羟基-17-((E)-2-羟基-1-(羟基亚氨基)乙基)-10,13-二甲基-6,7,8,9,10,11,12,13,14,15,16,17-十二氢-3H-环戊烷[a]菲-3-酮肟
按照上文一般的合成方法中合成路线I中所示的方法,用合适的起始原料制备化合物3,并分离得到(3Z)-3和(3E)-3。
化合物3(Z)-3:1H-NMR(600MHz,d6-DMSO)δH 0.630(m,1H),0.869-0.834(m,4H),1.253-1.120(m,1H),1.325(s,3H),1.368-1.352(m,1H),1.601-1.592(m,2H),1.756-1.713(m,2H),1.998-1.971(m,2H),2.602-2.523(m,2H),2.735(m,1H),4.162-4.131(m,1H),4.273-4.224(m,2H),4.402-4.394(m,1H),4.591-4.557(m,1H),4.806(s,1H),6.114-6.085(m,1H),6.352-6.327(d,1H),6.448(s,1H),10.573(s,1H),10.798(s,1H);13C(600MHz,d6-DMSO)δC 18.23,23.47,23.58,31.73,32.49,32.84,39.93,43.58,43.67,47.06,50.92,55.75,56.94,67.77,85.65,104.82,121.60,141.72,148.76,159.73,161.49;LRMS(ES+)[C21H30N2O5+H]的计算值391.3实验值391.2。
化合物3(E)-3:1H-NMR(600MHz,d6-DMSO)δH 0.627(m,1H),0.872-0.835(m,4H),1.250-1.122(m,1H),1.323(s,3H),1.364-1.357(m,1H),1.606-1.598(m,2H),1.768-1.709(m,2H),2.001-1.939(m,2H),2.589-2.478(m,2H),2.732(m,1H),4.153-4.125(m,1H),4.263-4.231(m,2H),4.409-4.404(m,1H),4.590-4.574(m,1H),4.810(s,1H),5.707(s,1H),6.518-6.502(d,1H),6.779-6.762(m,1H),10.524(s,1H),10.796(s,1H);13C(600MHz,d6-DMSO)δC 18.24,23.34,23.47,31.75,32.47,32.86,39.94,43.53,43.64,47.02,50.94,55.73,56.69,67.68,85.72,112.23,113.74,145.95,149.06,156.83,159.74;LRMS(ES+)[C21H30N2O5+H]的计算值391.3实验值391.2。
实施例4
(6S,8S,9S,10R,11S,13S,14S,17R)-11,17-二羟基-17-((E)-2-羟基-1-(羟基亚氨基)乙基)-6,10,13-三甲基-1,2,6,7,8,9,10,11,12,13,14,15,16,17-十四氢-3H-环戊烷[a]菲-3-酮肟
按照上文一般的合成方法中合成路线I中所示的方法,用合适的起始原料制备化合物4,并分离得到(3Z)-4和(3E)-4
化合物3(Z)-4:1H-NMR(600MHz,d6-DMSO)δH 0.635(m,1H),0.868-0.837(m,4H),1.053-1.032(d,3H),1.085-1.089(m,1H),1.156-1.127(m,1H),1.284-1.277(m,1H),1.323(s,3H),1.371-1.352(m,1H),1.603-1.585(m,2H),1.759-1.713(m,2H),1.996-1.965(m,2H),2.636-2.534(m,1H),2.738(m,1H),2.979-2.965(m,2H),4.166-4.135(m,1H),4.273-4.226(m,2H),4.405-4.399(m,1H),4.588-4.561(m,1H),4.809(s,1H),6.407(s,1H),10.127(s,1H),10.791(s,1H);13C(600MHz,d6-DMSO)δC18.22,18.65,23.47,23.61,30.82,31.71,32.74,32.84,38.75,39.95,43.52,43.68,47.05,50.92,55.73,56.96,67.73,85.65,101.52,148.59,159.71,162.47;LRMS(ES+)[C22H32N2O5+H]的计算值407.3实验值407.2。
化合物3(E)-4:1H-NMR(600MHz,d6-DMSO)δH 0.623(m,1H),0.873-0.834(m,4H),1.035-1.026(d,3H),1.089-1.082(m,1H),1.156-1.117(m,1H),1.282-1.274(m,1H),1.325(s,3H),1.367-1.358(m,1H),1.609-1.597(m,2H),1.759-1.708(m,2H),2.001-1.945(m,2H),2.514(m,1H),2.733(m,1H),3.124-3.037(m,2H),4.154-4.123(m,1H),4.268-4.232(m,2H),4.406-4.401(m,1H),4.590-4.575(m,1H),4.811(s,1H),5.701(s,1H),10.124(s,1H),10.791(s,1H);13C(600MHz,d6-DMSO)δC 18.23,18.56,23.33,23.47,30.21,31.78,32.02,32.84,39.07,39.93,43.44,43.65,47.01,50.93,55.74,56.69,67.70,85.71,113.21,149.03,157.86,159.74;LRMS(ES+)[C22H32N2O5+H]的计算值407.3实验值407.2。
实施例5
(2E)-2-((8S,9S,10R,11S,13S,14S,17R)-11,17-二羟基-3-(羟基亚胺基)-10,13-二甲基-2,3,6,7,8,9,10,11,12,13,14,15,16,17-十四氢-1H-环戊烷[a]菲-17-基)-2-(羟基亚胺基)乙酸乙酯
按照上文一般的合成方法中合成路线I、II中所示的方法,用合适的起始原料制备化合物5,并分离得到(3Z)-5和(3E)-5
化合物3(Z)-5:1H-NMR(600MHz,d6-DMSO)δH 0.631(m,1H),0.868-0.837(m,4H),1.085-1.089(m,1H),1.156-1.127(m,1H),1.284-1.277(m,1H),1.323(s,3H),1.371-1.352(m,1H),1.603-1.585(m,2H),1.759-1.713(m,2H),1.996-1.965(m,2H),2.602-2.523(m,2H),2.688(s,3H),2.738(m,1H),2.979-2.965(m,2H),4.166-4.135(m,1H),4.273-4.226(m,2H),4.405-4.399(m,1H),4.809(s,1H),6.407(s,1H),10.127(s,1H),10.791(s,1H);13C(600MHz,d6-DMSO)δC 18.22,22.93,23.47,23.61,30.82,31.71,32.48,32.84,38.75,39.95,43.52,43.68,47.05,50.92,55.73,56.96,67.73,85.65,101.52,148.59,159.71,162.47,168.91;LRMS(ES+)[C23H34N2O6+H]的计算值435.3实验值435.2。
化合物3(E)-5:1H-NMR(600MHz,d6-DMSO)δH 0.624(m,1H),0.872-0.835(m,4H),1.091-1.078(m,1H),1.154-1.116(m,1H),1.283-1.275(m,1H),1.324(s,3H),1.366-1.359(m,1H),1.610-1.595(m,2H),1.754-1.706(m,2H),2.002-1.945(m,2H),2.603-2.522(m,2H),2.687(s,3H),2.735(m,1H),3.126-3.034(m,2H),4.155-4.124(m,1H),4.267-4.231(m,2H),4.408-4.403(m,1H),4.813(s,1H),5.704(s,1H),10.127(s,1H),10.793(s,1H);13C(600MHz,d6-DMSO)δC 18.23,22.88,23.33,23.47,30.21,31.78,32.02,32.44,39.06,39.94,43.45,43.66,47.02,50.94,55.73,56.68,67.71,85.72,113.23,149.07,157.88,159.75,168.95;LRMS(ES+)[C23H34N2O6+H]的计算值435.3实验值435.2。
实施例6
(8S,9S,10R,11S,13S,14S,16S,17R)-11,17-二羟基-17-((E)-2-羟基-1-(羟基亚氨基)乙基)-10,13,16-三甲基-6,7,8,9,10,11,12,13,14,15,16,17-十二氢-3H-环戊烷[a]菲-3-酮肟
按照上文一般的合成方法中合成路线I、II中所示的方法,用合适的起始原料制备化合物6,并分离得到(3Z)-6和(3E)-6。
化合物3(Z)-6:1H-NMR(600MHz,d6-DMSO)δH 0.630(m,1H),0.870-0.832(m,7H),1.252-1.123(m,1H),1.324(s,3H),1.602-1.593(m,2H),1.755-1.716(m,3H),2.001-1.974(m,2H),2.605-2.526(m,2H),4.162-4.135(m,1H),4.272-4.228(m,2H),4.403-4.397(m,1H),4.587-4.561(m,1H),4.806(s,1H),6.112-6.084(m,1H),6.353-6.328(d,1H),6.451(s,1H),10.569(s,1H),10.793(s,1H);13C(600MHz,d6-DMSO)δC 17.28,18.22,23.57,27.38,31.74,32.45,38.89,39.93,43.66,43.57,47.07,50.90,55.74,56.94,67.76,88.93,104.84,121.63,141.70,148.75,159.70,161.39;LRMS(ES+)[C22H32N2O5+H]的计算值405.43实验值405.3。
化合物3(E)-6:1H-NMR(600MHz,d6-DMSO)δH 0.629(m,1H),0.872-0.8345(m,7H),1.251-1.123(m,1H),1.325(s,3H),1.604-1.596(m,2H),1.765-1.711(m,3H),2.001-1.969(m,2H),2.593-2.481(m,2H),4.152-4.137(m,1H),4.269-4.233(m,2H),4.405-4.402(m,1H),4.590-4.574(m,1H),4.810(s,1H),5.702(s,1H),6.513-6.501(d,1H),6.776-6.761(m,1H),10.523(s,1H),10.794(s,1H);13C(600MHz,d6-DMSO)δC17.27,18.23,23.34,27.38,31.76,32.47,38.85,39.94,43.56,43.64,47.03,50.93,55.74,56.67,67.69,88.98,112.24,113.72,145.95,149.07,156.85,159.78;LRMS(ES+)[C22H32N2O5+H]的计算值405.43实验值405.3。
实施例7
(6aS,6bR,7S,8aS,8bR,11aR,12aS,12bS)-6b-氟-7-羟基-8b-((E)-2-羟基-1-(羟基亚氨基)乙基)-6a,8a,10,10-四甲基-1,2,6a,6b,7,8,8a,8b,11a,12,12a,12b-十二氢-4H-萘并[2',1':4,5]茚并[1,2-d][1,3]二氧杂环-4-酮肟
按照上文一般的合成方法中合成路线I、III中所示的方法,用合适的起始原料制备化合物7,并分离得到(3Z)-7和(3E)-7。
化合物3(Z)-7:1H-NMR(600MHz,d6-DMSO)δH 0.731(m,1H),0.877-0.852(m,4H),1.233(s,6H),1.287-1.198(m,1H),1.347(s,3H),1.611-1.597(m,1H),1.783-1.774(m,2H),1.998-1.972(m,2H),2.798(m,2H),3.986(m,1H),4.174-4.163(m,1H),4.285-4.273(m,2H),4.411-4.402(m,1H),4.587-4.559(m,1H),6.118-6.097(m,1H),6.361-6.333(d,1H),6.442(s,1H),10.574(s,1H),10.799(s,1H);13C(600MHz,d6-DMSO)δC 18.34,23.62,26.57,33.86,33.92,34.37,39.94,43.51,43.69,47.08,50.92,55.76,70.83,83.49,96.91,100.24,104.82,121.62,123.13,141.72,148.75,159.73,161.49;LRMS(ES+)[C23H33F2N2O6+H]的计算值465.3实验值465.2。
化合物3(E)-7:1H-NMR(600MHz,d6-DMSO)δH 0.728(m,1H),0.874-0.833(m,4H),1.234(s,6H),1.256-1.121(m,1H),1.326(s,3H),1.609-1.593(m,1H),1.762-1.723(m,2H),2.003-1.965(m,2H),2.788(m,2H),3.979(m,1H),4.154-4.123(m,1H),4.269-4.253(m,2H),4.407-4.403(m,1H),4.591-4.570(m,1H),5.706(s,1H),6.513-6.504(d,1H),6.779-6.759(m,1H),10.522(s,1H),10.793(s,1H);13C(600MHz,d6-DMSO)δC 18.33,23.64,26.56,33.85,33.94,34.38,39.93,43.47,43.64,47.03,50.93,55.75,70.82,83.56,96.94,100.23,112.25,113.72,121.63,145.97,149.09,156.88,159.74;LRMS(ES+)[C23H33F2N2O6+H]的计算值465.3实验值465.2。
实施例8
(2S,6aS,6bR,7S,8aS,8bR,11aR,12aS,12bS)-2,6b-二氟-7-羟基-8b-((E)-2-羟基-1-(羟基亚胺)乙基)-6a,8a,10,10-四甲基-1,2,6a,6b,7,8,8a,8b,11a,12,12a,12b-十二氢-4H-萘并[2',1':4,5]茚并[1,2-d][1,3]二氧杂醇-4-酮肟
按照上文一般的合成方法中合成路线I、III中所示的方法,用合适的起始原料制备化合物8,并分离得到(3Z)-8和(3E)-8。
化合物3(Z)-8:1H-NMR(600MHz,d6-DMSO)δH 0.702(m,1H),0.876-0.853(m,4H),1.235(s,6H),1.258-1.121(m,1H),1.331(s,3H),1.613-1.598(m,1H),1.782-1.775(m,2H),1.871-1.859(m,1H),1.998-1.972(m,1H),3.983(m,1H),4.093-4.087(m,1H),4.172-4.165(m,1H),4.289-4.276(m,2H),4.404(m,1H),4.583-4.563(m,1H),6.124-6.102(m,1H),6.364-6.341(d,1H),6.573(s,1H),10.576(s,1H),10.801(s,1H);13C(600MHz,d6-DMSO)δC 18.35,23.64,26.58,33.87,34.38,39.97,43.59,43.73,47.11,50.94,55.75,70.85,83.47,88.87,96.94,100.25,104.83,121.60,123.14,141.73,148.76,159.72,161.03;LRMS(ES+)[C24H32F2N2O6+H]的计算值483.2实验值483.3。
化合物3(E)-8:1H-NMR(600MHz,d6-DMSO)δH 0.703(m,1H),0.874-0.851(m,4H),1.234(s,6H),1.256-1.124(m,1H),1.328(s,3H),1.610-1.595(m,1H),1.771-1.765(m,2H),1.872-1.861(m,1H),2.002-1.974(m,1H),3.977(m,1H),4.091-4.085(m,1H),4.152-4.126(m,1H),4.271-4.254(m,2H),4.406(m,1H),4.587-4.569(m,1H),5.784(s,1H),6.521-6.510(d,1H),6.775-6.761(m,1H),10.523(s,1H),10.789(s,1H);13C(600MHz,d6-DMSO)δC 18.34,23.65,26.57,33.86,34.37,39.95,43.58,43.75,47.08,50.95,55.76,70.83,83.54,96.96,100.24,112.24,113.75,121.62,145.96,149.11,156.87,159.72;LRMS(ES+)[C24H32F2N2O6+H]的计算值483.2实验值483.3。
实施例9
(6S,8S,9S,10R,11S,13S,14S,17R,E)-17-((E)-1-(乙氧基亚胺基)-2-羟乙基)-11,17-二羟基-6,10,13-三甲基-6,7,8,9,10,11,12,13,14,15,16,17-十二氢-3H-环戊烷[a]菲-3-酮O-乙基肟
按照上文一般的合成方法中合成路线I、IV中所示的方法,用合适的起始原料制备化合物9,并分离得到(3Z)-9和(3E)-9。
化合物3(Z)-9:1H-NMR(600MHz,d6-DMSO)δH 0.629(m,1H),0.870-0.835(m,4H),0.987-0.975(m,6H),1.051-1.035(d,3H),1.254-1.119(m,1H),1.323(s,3H),1.396-1.354(m,1H),1.604-1.590(m,2H),1.758-1.714(m,2H),1.995-1.969(m,2H),2.636-2.536(m,1H),2.734(m,1H),3.882-3.754(m,4H),4.164-4.132(m,1H),4.274-4.225(m,2H),4.406-4.397(m,1H),4.589-4.560(m,1H),4.807(s,1H),6.116-6.087(m,1H),6.354-6.329(d,1H),6.446(s,1H),;13C(600MHz,d6-DMSO)δC 13.9,18.26,18.64,23.47,23.62,31.73,32.75,32.84,39.93,43.52,43.66,47.09,50.95,55.79,56.97,66.93,67.02,67.75,85.69,104.84,121.61,141.76,148.73,159.74,161.48;LRMS(ES+)[C26H40N2O5+H]的计算值461.3实验值461.4。
化合物3(E)-9:1H-NMR(600MHz,d6-DMSO)δH 0.631-0.624(m,1H),0.873-0.835(m,4H),0.985-0.974(m,6H),1.035-1.028(d,3H),1.253-1.121(m,1H),1.326(s,3H),1.365-1.351(m,1H),1.604-1.592(m,2H),1.760-1.713(m,2H),2.002-1.954(m,2H),2.516(m,1H),2.735(m,1H),3.796-3.728(m,4H),4.157-4.128(m,1H),4.269-4.235(m,2H),4.407-4.401(m,1H),4.590-4.571(m,1H),4.804(s,1H),5.702(s,1H),6.517-6.506(d,1H),6.801-6.762(m,1H);13C(600MHz,d6-DMSO)δC 14.01,18.24,18.58,23.33,23.49,31.75,32.66,32.83,39.96,43.41,43.64,47.02,50.93,55.85,56.70,67.72,85.73,112.21,113.76,145.94,149.07,156.83,159.74;LRMS(ES+)[C26H40N2O5+H]的计算值461.3实验值461.4。
实施例10
(8S,9S,10R,11S,13S,14S,16R,17S)-11-羟基-17-(2-羟基乙酰基)-10,13,16-三甲基-6,7,8,9,10,11,12,13,14,15,16,17-十二氢-3H-环戊烷[a]菲-3-酮
按照上文一般的合成方法中合成路线I中所示的方法,用合适的起始原料制备化合物10,并分离得到(3Z)-10和(3E)-10。
化合物3(Z)-10:1H-NMR(600MHz,d6-DMSO)δH 0.630(m,1H),0.870-0.832(m,4H),0.989-0.975(s,3H),1.254-1.126(m,1H),1.327(s,3H),1.602-1.593(m,2H),1.755-1.716(m,3H),1.896-1.874(m,1H),2.003-1.977(m,2H),2.606-2.528(m,2H),4.163-4.142(m,1H),4.273-4.231(m,2H),4.405-4.396(m,1H),4.591-4.575(m,1H),6.113-6.087(m,1H),6.354-6.329(m,1H),6.453(s,1H),10.567(s,1H),10.797(s,1H);13C(600MHz,d6-DMSO)δC17.21,18.32,23.51,31.42,31.96,38.95,39.71,40.03,42.97,43.92,45.88,49.73,56.81,56.89,67.76,85.67,104.83,121.59,141.73,148.76,159.72,161.47;LRMS(ES+)[C22H32N2O4+H]的计算值389.3实验值389.2。
化合物3(E)-10:1H-NMR(600MHz,d6-DMSO)δH 0.628(m,1H),0.873-0.834(m,4H),0.988-0.976(s,3H),1.253-1.121(m,1H),1.327(s,3H),1.606-1.594(m,2H),1.764-1.712(m,3H),1.894-1.873(m,1H),1.998-1.962(m,2H),2.597-2.485(m,2H),4.155-4.134(m,1H),4.267-4.231(m,2H),4.408-4.403(m,1H),4.588-4.572(m,1H),5.704(s,1H),6.511-6.503(d,1H),6.778-6.764(m,1H),10.522(s,1H),10.793(s,1H);13C(600MHz,d6-DMSO)δC17.25,18.26,23.37,31.39,31.87,38.93,39.69,40.01,42.92,43.89,45.86,49.71,56.76,56.85,67.70,85.64,112.19,113.78,145.94,149.11,156.87,159.82;LRMS(ES+)[C22H32N2O4+H]的计算值389.3实验值389.2。
实施例11
(2E)-2-(乙氧基亚氨基)-2-((8S,9S,10R,11S,13S,14S,16R,17R)-3-(乙氧基亚氨基)-11,17-二羟基-10,13,16-三甲基-6,7,8,9,10,11,12,13,14,15,16,17-十二氢-3H-环戊[a]菲-17-基)乙酸乙酯
按照上文一般的合成方法中合成路线I、IV中所示的方法,用合适的起始原料制备化合物11,并分离得到(3Z)-11和(3E)-11。
化合物3(Z)-10:1H-NMR(600MHz,d6-DMSO)δH 0.641(m,1H),0.877-0.841(m,4H),0.992-0.975(s,9H),1.254-1.126(m,1H),1.327(s,3H),1.602-1.593(m,2H),1.755-1.716(m,3H),2.003-1.977(m,2H),2.606-2.528(m,2H),2.688(s,3H),3.882-3.754(m,4H),4.163-4.142(m,1H),4.273-4.231(m,2H),4.405-4.396(m,1H),4.806(s,1H),6.113-6.087(m,1H),6.354-6.329(m,1H),6.453(s,1H);13C(600MHz,d6-DMSO)δC 13.56,17.21,18.33,23.53,30.35,31.63,32.58,36.83,39.98,42.36,43.62,46.11,50.83,56.89,56.93,67.74,69.81,69.84 88.87,104.85,121.54,141.76,148.74,159.71,161.45,169.88;LRMS(ES+)[C28H42N2O6+H]的计算值503.3实验值503.2。
化合物3(E)-10:1H-NMR(600MHz,d6-DMSO)δH 0.633(m,1H),0.875-0.837(m,4H),0.987-0.979(s,9H),1.2543-1.120(m,1H),1.329(s,3H),1.604-1.592(m,2H),1.761-1.718(m,3H),1.997-1.965(m,2H),2.596-2.483(m,2H),2.687(s,3H),3.876-3.752(m,4H),4.154-4.132(m,1H),4.264-4.230(m,2H),4.404-4.398(m,1H),4.811(s,1H),5.706(s,1H),6.509-6.501(d,1H),6.776-6.763(m,1H);13C(600MHz,d6-DMSO)δC 13.55,17.23,18.34,23.51,30.39,31.67,32.56,36.76,39.96,42.37,43.69,46.13,50.79,56.86,56.96,67.72,69.79,69.83,88.84,112.21,113.76,145.92,149.15,156.86,159.76,169.87;LRMS(ES+)[C28H42N2O6+H]的计算值503.3实验值503.2。
实施例12
(2E)-2-((8S,9R,10S,11S,13S,14S,16S,17R)-9-氯-11,17-二羟基-3-(羟基亚氨基)-10,13,16-三甲基-6,7,8,9,10,11,12,13,14,15,16,17-十二氢-3H-环戊烷[a]菲-17-基)-2-(羟基亚氨基)丙酸乙酯
按照上文一般的合成方法中合成路线I、II中所示的方法,用合适的起始原料制备化合物12,并分离得到(3Z)-12和(3E)-12。
化合物3(Z)-12:1H-NMR(600MHz,d6-DMSO)δH 0.629(m,1H),0.872-0.833(m,7H),1.249-1.117(m,4H),1.326(s,3H),1.601-1.597(m,1H),1.754-1.718(m,3H),2.002-1.976(m,2H),2.601-2.522(m,4H),4.159-4.134(m,1H),4.274-4.229(m,2H),4.402-4.398(m,1H),4.811(s,1H),6.109-6.085(m,1H),6.353-6.321(d,1H),6.452(s,1H),10.574(s,1H),10.792(s,1H);13C(600MHz,d6-DMSO)δC 10.26,17.27,18.24,23.58,27.29,27.36,31.76,32.44,38.90,39.96,43.55,43.67,47.04,50.91,55.76,56.93,67.77,88.96,104.85,121.63,141.76,148.73,159.74,161.46,171.57;LRMS(ES+)[C25H35FN2O6+H]的计算值496.2实验值496.3。
化合物3(E)-12:1H-NMR(600MHz,d6-DMSO)δH 0.631(m,1H),0.871-0.837(m,7H),1.252-1.121(m,4H),1.322(s,3H),1.603-1.597(m,1H),1.761-1.723(m,3H),1.998-1.967(m,2H),2.596-2.486(m,4H),4.154-4.133(m,1H),4.272-4.234(m,2H),4.406-4.397(m,1H),4.809(s,1H),5.698(s,1H),6.508-6.497(d,1H),6.772-6.760(m,1H),10.528(s,1H),10.791(s,1H);13C(600MHz,d6-DMSO)δC 10.24,17.25,18.23,23.39,27.31,27.40,31.75,32.48,38.89,39.93,43.54,43.67,47.04,50.93,55.77,56.71,67.68,88.92,112.21,113.78,145.96,149.11,156.82,159.77,171.52;LRMS(ES+)[C25H35FN2O6+H]的计算值496.2实验值496.3。
实施例13
(6aR,6bS,7S,8aS,8bR,11aR,12aS,12bS)-7-羟基-8b-((E)-2-羟基-1-(羟基亚氨基)乙基)-6a,8a-二甲基-10-丙基-1,2,6a,6b,7,8,8a,8b,11a,12,12a,12b-十二氢-4H-萘并[2',1':4,5]吲哚[1,2-d][1,3]二氧杂环-4-酮肟
按照上文一般的合成方法中合成路线I、III中所示的方法,用合适的起始原料制备化合物13,并分离得到(3Z)-13和(3E)-13。
化合物3(Z)-13:1H-NMR(600MHz,d6-DMSO)δH 0.637(m,1H),0.873-0.858(m,4H),0.893-0.882(m,3H),1.233(s,2H),1.272-1.125(m,1H),1.347(s,3H),1.402(m,1H),1.613-1.602(m,3H),1.781-1.779(m,2H),1.994-1.961(m,2H),2.679-2.657(m,2H),3.986(m,1H),4.170-4.168(m,1H),4.283-4.269(m,2H),4.407-4.404(m,1H),4.583-4.563(m,1H),5.396(m,1H),6.118-6.097(m,1H),6.361-6.333(d,1H),6.442(s,1H),10.574(s,1H),10.799(s,1H);13C(600MHz,d6-DMSO)δC 13.22,14.57,18.36,23.55,33.88,33.91,34.36,36.69,42.85,43.54,43.61,46.97,52.38,55.76,56.98,70.21,89.97,96.91,103.62104.83,120.31,141.75,148.73,159.76,161.46;LRMS(ES+)[C25H36N2O6+H]的计算值461.3实验值461.4。
化合物3(E)-13:1H-NMR(600MHz,d6-DMSO)δH 0.635(m,1H),0.876-0.842(m,4H),0.891-0.884(m,3H),1.231(s,2H),1.269-1.123(m,1H),1.331(s,3H),1.398(m,1H),1.7-1.594(m,3H),1.767-1.728(m,2H),2.001-1.967(m,2H),2.749(m,2H),3.982(m,1H),4.163-4.139(m,1H),4.271-4.262(m,2H),4.409-4.405(m,1H),4.590-4.568(m,1H),5.704(s,1H),6.517-6.501(d,1H),6.778-6.757(m,1H),10.528(s,1H),10.796(s,1H);13C(600MHz,d6-DMSO)δC 13.26,14.55,18.34,23.57,33.87,33.89,34.35,36.72,42.83,43.49,43.63,46.94,52.37,55.74,56.97,70.24,89.95,96.93,103.65,112.29,113.74,120.33,145.94,149.03,156.86,159.73;LRMS(ES+)[C25H36N2O6+H]的计算值461.3实验值461.4。
实施例14
(2E)-2-((8S,9R,10S,11S,13S,14S,16R,17R)-9-氟-11,16,17-三羟基-3-(羟基亚氨基)-10,13-二甲基-6,7,8,9,10,11,12,13,14,15,16,17-十二氢-3H-环戊烷[a]菲仑-17-基)-2-(羟基亚氨基)丙酸乙酯
按照上文一般的合成方法中合成路线I、II中所示的方法,用合适的起始原料制备化合物14,并分离得到(3Z)-14和(3E)-14。
化合物3(Z)-14:1H-NMR(600MHz,d6-DMSO)δH 0.728(m,1H),0.879-0.854(m,4H),1.211-1.199(m,3H),1.284-1.187(m,1H),1.347(s,3H),1.611-1.597(m,1H),1.783-1.774(m,2H),1.998-1.972(m,2H),2.399-2.367(m,2H),2.798(m,2H),3.873(m,1H),4.161-4.148(m,2H),4.376-4.363(m,1H),4.411-4.402(m,1H),5.223(s,1H),5.416(m,1H),6.114-6.093(m,1H),6.358-6.331(d,1H),6.438(s,1H),10.571(s,1H),10.795(s,1H);13C(600MHz,d6-DMSO)δC 10.32,18.21,23.32,23.57,27.46,33.89,33.94,34.29,39.91,43.50,43.71,47.08,50.81,56.69,70.81,82.34,92.73,100.21,104.84,121.60,141.71,148.77,159.72,161.45;LRMS(ES+)[C24H33F1N2O7+H]的计算值481.2实验值481.3。
化合物3(E)-14:1H-NMR(600MHz,d6-DMSO)δH 0.731(m,1H),0.872-0.835(m,4H),1.208-1.198(m,3H),1.253-1.119(m,1H),1.329(s,3H),1.607-1.592(m,1H),1.765-1.738(m,2H),2.001-1.969(m,2H),2.334-2.359(m,2H),2.787(m,2H),3.897(m,1H),4.154-4.123(m,2H),4.272-4.259(m,1H),4.406-4.401(m,1H),5.219(s,1H),5.408(m,1H),5.704(s,1H),6.511-6.502(d,1H),6.774-6.758(m,1H),10.523(s,1H),10.798(s,1H);13C(600MHz,d6-DMSO)δC 10.29,18.24,23.34,23.56,27.45,33.88,33.95,34.31,39.92,43.49,43.69,47.05,50.83,56.68,70.79,82.36,92.72,100.22,112.23,113.74,145.95,149.07,156.86,159.73;LRMS(ES+)[C24H33F1N2O7+H]的计算值481.2实验值481.3。
实施例15
(8S,9R,10S,11S,13S,14S,16S,17R)-9-氟-11-羟基-17-((E)-2-羟基-1-(羟基亚氨基)乙基)-3-(羟基亚氨基)-10,13,16-三甲基-6,7,8,9,10,11,12,13,14,15,16,17-十二氢-3H-环戊酸菲-17-基丁酸盐
按照上文一般的合成方法中合成路线I、II中所示的方法,用合适的起始原料制备化合物15,并分离得到(3Z)-15和(3E)-15。
化合物3(Z)-15:1H-NMR(600MHz,d6-DMSO)δH 0.631(m,1H),0.872-0.833(m,7H),1.109-0.998(m,3H),1.249-1.119(m,1H),1.331(s,3H),1.601-1.597(m,1H),1.665-1.621(m,2H),1.754-1.718(m,2H),1.998-1.975(m,2H),2.136-1.109(m,1H),2.322-2.317(m,2H),2.603-2.524(m,2H),4.145-4.122(m,1H),4.275-4.227(m,2H),4.403-4.396(m,1H),4.589-4.560(m,1H),6.113-6.086(m,1H),6.359-6.324(d,1H),6.448(s,1H),10.578(s,1H),10.799(s,1H);13C(600MHz,d6-DMSO)δC 14.11,17.21,18.25,18.46,23.52,23.66,31.62,32.49,32.79,36.32,40.11,43.46,43.62,47.87,51.12,55.72,67.77,88.91,100.01,104.83,121.67,141.72,148.75,159.71,161.48,172.13;LRMS(ES+)[C26H37FN2O6+H]的计算值493.3实验值493.2。
化合物3(E)-15:1H-NMR(600MHz,d6-DMSO)δH 0.629(m,1H),0.873-0.834(m,7H),1.107-0.997(m,3H),1.246-1.117(m,1H),1.322(s,3H),1.602-1.599(m,1H),1.661-1.618(m,2H),1.755-1.721(m,2H),1.996-1.972(m,2H),2.133-1.107(m,1H),2.317-2.311(m,2H),2.597-2.493(m,2H),4.142-4.120(m,1H),4.272-4.225(m,2H),4.404-4.395(m,1H),4.588-4.571(m,1H),5.683(s,1H),6.507-6.494(d,1H),6.770-6.758(m,1H),10.526(s,1H),10.801(s,1H);13C(600MHz,d6-DMSO)δC 14.09,17.24,18.23,18.44,23.41,23.64,31.64,32.47,32.75,36.33,40.08,43.42,43.63,47.84,51.11,55.74,67.69,88.90,99.98,112.19,113.75,145.93,149.13,156.83,159.74,172.11;LRMS(ES+)[C26H37FN2O6+H]的计算值493.3实验值493.2。
实施例16
(8S,9S,10R,11S,13S,14S,17R)-11-羟基-3-(羟基亚氨基)-17-((E)-1-(羟基亚氨基)乙基)-10,13-二甲基-6,7,8,9,10,11,12,13,14,15,16,17-十二氢-3H-环戊烷[a]菲-17-基丙酸盐
按照上文一般的合成方法中合成路线I、II中所示的方法,用合适的起始原料制备化合物16,并分离得到(3Z)-16和(3E)-16。
化合物3(Z)-16:1H-NMR(600MHz,d6-DMSO)δH 0.628(m,1H),0.868-0.835(m,4H),1.226-1.213(m,3H),1.253-1.118(m,1H),1.325(s,3H),1.398-1.364(m,1H),1.606-1.590(m,2H),1.760-1.715(m,2H),1.998-1.972(m,2H),2.339-2.297(m,2H),2.606-2.527(m,2H),2.755(m,1H),3.037(s,3H),4.273-4.224(m,1H),4.402-4.394(m,1H),6.118-6.086(m,1H),6.355-6.329(d,1H),6.447(s,1H),10.575(s,1H),10.794(s,1H);13C(600MHz,d6-DMSO)δC 9.97,10.92,18.34,23.56,23.62,28.06,31.67,32.50,32.72,39.98,43.58,43.69,46.24,50.94,56.95,67.72,95.58,104.84,121.59,141.72,148.77,159.71,161.48,173.36;LRMS(ES+)[C24H34N2O5+H]的计算值431.2实验值431.3。
化合物3(E)-16:1H-NMR(600MHz,d6-DMSO)δH 0.629(m,1H),0.870-0.834(m,4H),1.224-1.210(m,3H),1.250-1.121(m,1H),1.322(s,3H),1.375-1.363(m,1H),1.603-1.595(m,2H),1.755-1.709(m,2H),2.002-1.975(m,2H),2.331-2.295(m,2H),2.603-2.532(m,2H),2.745(m,1H),3.035(s,3H),4.271-4.228(m,2H),4.403-4.398(m,1H),5.704(s,1H),6.515-6.501(d,1H),6.776-6.758(m,1H),10.520(s,1H),10.791(s,1H);13C(600MHz,d6-DMSO)δC 9.98,10.89,18.33,23.46,23.61,28.04,31.63,32.46,32.84,39.97,43.54,43.66,46.20,50.92,56.97,67.74,95.57,112.19,113.73,145.97,149.08,156.85,159.71,173.34;LRMS(ES+)[C24H34N2O5+H]的计算值431.2实验值431.3。
实施例17
(6S,8S,9S,10R,11S,13S,14S,17R,E)-11-羟基-17-((E)-2-羟基-1-(羟基亚氨基)乙基)-3-(羟基亚氨基)-6,10,13-三甲基-6,7,8,9,10,11,12,13,14,15,16,17-十二氢-3H-环戊烷[a]菲-17-基戊酸盐
按照上文一般的合成方法中合成路线I、II中所示的方法,用合适的起始原料制备化合物17,并分离得到(3Z)-17和(3E)-17。
化合物3(Z)-17:1H-NMR(600MHz,d6-DMSO)δH 0.628(m,1H),0.869-0.833(m,4H),0.942-0.921(m,3H),1.053-1.033(d,3H),1.253-1.117(m,1H),1.325(s,3H),1.387-1.334(m,2H),1.498-1.424(m,1H),1.604-1.588(m,2H),1.755-1.702(m,4H),1.996-1.971(m,2H),2.429-2.402(m,2H),2.634-2.532(m,1H),2.789(m,1H),4.160-4.129(m,1H),4.272-4.227(m,2H),4.403-4.396(m,1H),4.591-4.562(m,1H),6.115-6.089(m,1H),6.353-6.331(d,1H),6.446(s,1H),10.575(s,1H),10.794(s,1H);13C(600MHz,d6-DMSO)δC 13.92,18.34,18.61,22.37,23.57,23.61,27.59,31.65,32.57,32.74,33.98,40.13,43.52,43.69,45.02,50.99,56.32,56.95,67.63,89.34,104.83,121.60,141.72,148.75,159.73,161.48,173.24;LRMS(ES+)[C27H40N2O6+H]的计算值489.3实验值489.4。
化合物3(E)-17:1H-NMR(600MHz,d6-DMSO)δH 0.623(m,1H),0.874-0.846(m,4H),0.940-0.918(m,3H),1.033-1.018(d,3H),1.252-1.120(m,1H),1.326(s,3H),1.385-1.327(m,2H),1.495-1.443(m,1H),1.603-1.592(m,2H),1.762-1.701(m,4H),2.002-1.958(m,2H),2.411-2.387(m,2H),2.514(m,1H),2.786(m,1H),4.156-4.125(m,1H),4.262-4.230(m,2H),4.410-4.405(m,1H),4.590-4.568(m,1H),5.704(s,1H),6.516-6.500(d,1H),6.781-6.758(m,1H),10.523(s,1H),10.795(s,1H);13C(600MHz,d6-DMSO)δC 13.91,18.29,18.60,22.35,23.37,23.52,27.61,31.69,32.58,32.75,33.96,40.14,43.51,43.67,45.03,50.98,56.33,56.96,67.71,89.28,112.21,113.76,145.94,149.08,156.85,159.73,173.22;LRMS(ES+)[C27H40N2O6+H]的计算值489.3实验值489.4。
实施例1-17所制备的化合物具有较强的抗痛风药效。具体实验如下。其中,以下实验所用实施例化合物均为各实施例制备的化合物的3位肟基团顺式、反式两种构型化合物等比例(1:1)混合物。
实验1
痛风是人类特有的疾病,痛风性关节炎是尿酸钠(MSU)沉积于局部关节组织引起的炎症反应。由于部分哺乳动物如鼠、兔等体内的嘌呤代谢途径与人类不同,所以无法从干扰嘌呤代谢紊乱的方法来构建痛风性关节炎的模型,故造成痛风性关节炎最直接的方法就是在模型动物的关节腔内直接注射MSU,该模型仅用来模拟痛风的局部关节炎症,适用于局部关节炎症状的观察,是目前筛选痛风药物抗炎作用的常见方法,具有稳定、易操作等优点。(参考文献:李娜,华龙,袁慧.痛风动物模型的研究进展[J].医学理论与实践,2016(24).)
采用尿酸钠(MSU)诱导的大鼠足跖肿胀模型检测以上实施例所制备的化合物的抗痛风效果,对照样品为甲泼尼龙。
实验方法:用MSU为致炎剂,注入大鼠后肢足跖皮下,造成足跖肿胀,然后测量足跖的容积,比较给药组和对照组足跖部的肿胀率和肿胀抑制率。实验当日先测各大鼠右后足容积(ml),致炎后测大鼠右后足容积,以致炎前后足容积之差为肿胀度,并计算足肿胀抑制率(肿胀抑制率%=(C-T)/C*100%;C=对照组的肿胀率%,T=治疗组的肿胀率%)。该法为筛选痛风药物抗炎作用的常用方法之一,模型稳定,易于操作。
1)给药剂量与抗痛风效果呈现正相关,具体实验结果如下:
2)在给大鼠足跖皮下注射MSU前一周给予大鼠不同剂量受试药物,灌胃给药,每天1次,连续7d。末次给药前标记并测定右后足周长,取两次测量的平均值为准。末次给药末次给药1h后,除空白对照组,其余各组动物给2%MSU 50μL,于致炎后1h测定足周长。在给予小鼠90mg/kg的甲泼尼龙,以上实施例化合物的结果如下:
本实验在给SD大鼠足跖皮下注射MSU前一周连续给予大鼠不同剂量的化合物,试验结果表明,以上实施例化合物的肿胀抑制率(%)在64.65%-99.74%范围内,且在安全剂量内,随着给药剂量的不断加大,化合物抗痛风的效果越强。以上实施例化合物与甲泼尼龙的缓解痛风症状肿胀抑制率显著高于甲泼尼龙(53.83%),且取代双肟基延长其体内代谢周期,具有较为长效的缓解痛风效果。
实验2
实施例1-17所制备的化合物具有较强的抗炎药效。
采用角叉菜胶致小鼠足肿胀模型检测以上实施例所制备的化合物的抗炎效果,对照样品为甲泼尼龙:
角叉菜胶致小鼠足肿胀模型是一个常用于评价或筛选药物抗炎作用的经典的急性炎症模型,当给小鼠足跖内注射角叉菜胶时能使大鼠局部毛细血管扩张、血管通透性增高、渗出、水肿等一系列类似于人体急性炎症的反应,故该模型在新药评价中应用非常广泛。
实验方法参考文献:杨欢,程笑,王月华,杜冠华.秦皮甲素对角叉菜胶致小鼠足肿胀及炎症的作用[J].中国新药杂志,2016(25):2322。
实验当日先测各小鼠右后足周长(cm),致炎后测小鼠右后足周长,以致炎前后足周长之差为肿胀度,并计算足肿胀抑制率(肿胀抑制率%=(C-T)/C*100%;C=对照组的肿胀率%,T=治疗组的肿胀率%)。
1)给药剂量与抗炎效果呈现正相关,具体结果如下:
2)灌胃给药,每天1次,连续7d。末次给药前标记并测定右后足周长,取两次测量的平均值为准。末次给药30min后,于小鼠右后足踝部注射20μL/只0.5%的角叉菜胶致炎,于致炎后180min测定足周长。在给予小鼠130mg/kg的甲泼尼龙,以上实施例化合物的结果如下:
本实验在给ICR小鼠足底注射0.5%角叉菜胶前一周连续给予小鼠不同剂量化合物,试验结果表明,以上实施例化合物的肿胀抑制率(%)在61.34%-96.44%范围内,且在安全剂量内,随着给药剂量的不断加大,化合物抗炎的效果越强;以上实施例所制备的化合物抑制足部肿胀效果优于甲泼尼龙(47.64%),且取代双肟基延长其体内代谢周期,具有较为长效的抗炎效果。
从生化指标来看,在发生炎症反应时,糖皮质激素受体α(GRa)蛋白表达水平受到抑制,糖皮质激素受体β(GRb)蛋白表达水平受到促进,促炎因子TNF-α蛋白表达大量升高,炎症保护因子IL-10的表达受到抑制。试验表明,以上实施例化合物会促进GRa蛋白表达,GRb蛋白表达,抑制TNF-α的升高,增加IL-10的量,直至恢复到正常水平。
实验3 急性毒性试验
根据国家食品药品监督管理局2005年3月颁发的《化学药物急性毒性试验技术指导原则》进行实验的设计。给药剂量为:4g/kg、4.91g/kg、6.14g/kg、7.68g/kg、9.6g/kg、12g/kg、15g/kg(可根据实际试验结果调整剂量),每个剂量组12只ICR小鼠。如果给药体积大于0.5ml,最好就分两次或多次给药(注:参照国标GB 15193.3-2014,若需要多次给药时,每次时间间隔4h~6h,给药前一天禁食)。急性毒性试验结果见下表:
死亡率(死亡数/12) |
4g/kg |
4.91g/kg |
6.14g/kg |
7.68g/kg |
9.6g/kg |
12g/kg |
15g/kg |
甲泼尼龙(p.o.) |
0/12 |
0/12 |
0/12 |
1/12 |
3/12 |
5/12 |
7/12 |
实施例1化合物(p.o.) |
0/12 |
0/12 |
0/12 |
0/12 |
0/12 |
0/12 |
0/12 |
实施例2化合物(p.o.) |
0/12 |
0/12 |
0/12 |
0/12 |
1/12 |
4/12 |
6/12 |
实施例3化合物(p.o.) |
0/12 |
0/12 |
0/12 |
0/12 |
0/12 |
0/12 |
1/12 |
实施例5化合物(p.o.) |
0/12 |
0/12 |
0/12 |
0/12 |
1/12 |
2/12 |
4/12 |
实施例8化合物(p.o.) |
0/12 |
0/12 |
0/12 |
0/12 |
0/12 |
0/12 |
1/12 |
实施例9化合物(p.o.) |
0/12 |
0/12 |
0/12 |
0/12 |
0/12 |
0/12 |
2/12 |
实施例10化合物(p.o.) |
0/12 |
0/12 |
1/12 |
1/12 |
3/12 |
4/12 |
5/12 |
实施例11化合物(p.o.) |
0/12 |
0/12 |
0/12 |
0/12 |
0/12 |
0/12 |
0/12 |
实施例14化合物(p.o.) |
0/12 |
0/12 |
0/12 |
0/12 |
1/12 |
1/12 |
3/12 |
实施例17化合物(p.o.) |
0/12 |
0/12 |
0/12 |
0/12 |
0/12 |
0/12 |
0/12 |
虽然,上文中已经用一般性说明及具体实施方案对本发明作了详尽的描述,但在本发明基础上,可以对之作一些修改或改进,这对本领域技术人员而言是显而易见的。因此,在不偏离本发明精神的基础上所做的这些修改或改进,均属于本发明要求保护的范围。